ALLR Company Profile and Key Details

ALLR has shown mixed momentum, gaining 1.75% over the past week and -19.44% over the past quarter, though year-to-date performance is up 7.41%. Short-term trend indicators are bullishly aligned (SMA20 8.54%, SMA50 -4.14%, SMA200 -14.72%). The stock’s 14-day RSI is 51.49 (neutral), while the ATR of 0.1 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -57.66% below its high and over 62.1% above its low. Average 10-day trading volume of 168.23 thousand shares is in line with the 3-month average of 178.64 thousand, indicating normal recent market interest.

Allarity Therapeutics, Inc. generated EPS of -$1.61 over the past year. Five-year average earnings growth is 84.72%. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 4 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $9.75 to $9.00. The high target offers 611.68% upside. The low target suggests 556.93% downside. The mean target is $9.38. This offers 584.67% upside. Allarity Therapeutics, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended November 14, 2025, missed forecasts by -17.39%. The prior quarter beat by -28.57%. Over the last six quarters, Apple has recorded several small beats. These include 1157.95% in May 14, 2024.

Allarity Therapeutics, Inc. has 15.82 million shares outstanding. The public float is 15.79 million shares, elevated short interest at 2.24% of float. This equals 353.88 thousand shares. The short ratio is 1.98 days. Institutional investors hold 6.71% of the float. Insiders own 2.67%.

Allarity Therapeutics, Inc. (NASDAQ:ALLR) closed at $1.37 USD, gaining $0.03 (2.24%) from the previous close of $1.34. The stock is currently mid-range between its 52-week high and low $0.77 and $2.35. With a market capitalization of about $21.67 million, Allarity Therapeutics, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.01). Key stats such as the average daily volume over the past year has been around 178.44 thousand shares, in line with its 52-week average. Headquartered in Boston, MA, Allarity Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Thomas H. Jensen, the company employs approximately 6 people and listed since December 21, 2021. Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology.

Allarity Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.29. This means the shares are trading above this model’s fair value.

Allarity Therapeutics, Inc. trades at a P/E ratio of -1.75, slightly below the S&P 500 average, with a price-to-sales ratio of 67.73 and a price-to-book ratio of 2.0 suggesting the stock is closer to book value. The P/FCF stands at 0.0, also below market averages.

Our AI price prediction model suggests that Allarity Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 4.38%, with price expected at $1.43 by May 07, 2026, within a range of $1.32 to $1.55 3-Month Outlook: Projected fall of -18.98%, reaching $1.11 by July 22, 2026, with a range of $1.00 to $1.19. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by April 23, 2027, within a range of $0.00 to $557.64.

Allarity Therapeutics, Inc. (NASDAQ:ALLR) shares are flat 7.41% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Allarity Therapeutics, Inc. trading at a premium to the broader market with a P/E of -1.75. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $9.38, suggesting 584.67% upside. Our AI forecast model points to short-term strength (4.38% over two weeks), a medium-term fall (-18.98% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.